NASDAQ$SCPX
Scorpius Holdings Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Heat Biologics reported financial results for Q3 2020, highlighting progress in oncology and COVID-19 vaccine programs and maintaining a solid balance sheet.
Heat Biologics reported a net loss of $8.9 million, or $0.06 per share, and grant revenue of $0.8 million for the third quarter of 2020. The company had $117.3 million in cash and short-term investments as of September 30, 2020, and is advancing its oncology and COVID-19 vaccine programs.
- Recognized $0.8 million of grant revenue for qualified expenditures under the CPRIT and NIH grants.
- Research and development expenses were $3.2 million.
- General and administrative expense was $6.6 million.
- Net loss attributable to Heat Biologics was approximately $8.9 million, or ($0.06) per basic and diluted share.
Headline financials
Revenue & EPS history
Scorpius Holdings · Revenue · Quarterly
$850K
Revenue by segment
Scorpius Holdings · $459K total across 1 segment · Q2 2021
- Grant and Contract Revenue$459K—100.0%
Forward guidance
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events.
Tailwinds
- PTX-35 being the potential first-in-class T- cell costimulatory antibody
- The expected enrollment of the Phase 1 PTX-35 study
- The potential of Heat’s COVID-19 vaccine to be used as either a standalone vaccine or in combination with other antibody-focused vaccine approaches to enhance prophylactic protection
- The combination of Heat’s gp96 platform in a single therapy holding enormous promise in the prevention and treatment of cancer and infectious diseases, such as COVID-19
- Heat’s capital providing a significant runway to achieve a number of important clinical milestones that will drive value for shareholders in the months and years ahead
Headwinds
- The ability of Heat's vaccine platform to provide protection against COVID-19
- The ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results
- The ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19
- Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements
- Regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-0.3%
Avg return
Earnings day
+100.8%
Avg return
5 days after
+129.2%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+5.2%
Q1 2021
Best reaction
-9.6%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +0.0% | +1350.0% | +3100.0% | |
| Q2 2025 | +0.0% | +900.0% | -60.0% | |
| Q1 2025 | -1.4% | +0.7% | +4.1% | |
| Q4 2024 | +0.0% | -1.5% | -2.9% | |
| Q1 2026 | +2.8% | -41.4% | -41.1% | |
| Q1 2024 | +2.8% | -41.4% | -41.1% | |
| Q3 2024 | +3.5% | +12.6% | -35.6% | |
| Q4 2023 | +0.0% | +2.1% | -19.1% | |
| Q3 2023 | -0.8% | -13.7% | -34.5% | |
| Q2 2023 | -1.6% | -12.9% | -2.9% | |
| Q1 2023 | -0.0% | -4.0% | -24.6% | |
| Q4 2022 | -0.0% | -4.0% | -24.6% | |
| Q3 2022 | +2.3% | -4.4% | -33.6% | |
| Q2 2022 | +0.4% | -11.5% | -22.2% | |
| Q1 2022 | -1.0% | -5.8% | -23.3% | |
| Q4 2021 | -9.4% | +12.4% | +17.9% | |
| Q3 2021 | -2.5% | -7.2% | -21.6% | |
| Q2 2021 | +1.2% | -4.3% | -4.1% | |
| Q1 2021 | +5.2% | +6.2% | -0.7% | |
| Q4 2020 | +1.8% | -8.9% | -10.3% | |
| Q3 2020 | -9.6% | -7.0% | -7.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro